Ventrus Biosciences, Inc. (Nasdaq: VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced positive results from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE